Riazuelo Lucas, Planat-Bénard Valérie, Vinel Alexia, Laurencin Sara, Casteilla Louis, Kémoun Philippe, Marty Mathieu, Monsarrat Paul
Oral Medicine Department and CHU de Toulouse, Toulouse Institute of Oral Medicine and Science, Toulouse, France.
RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, ENVT, Université P. Sabatier, Toulouse, France.
Int Dent J. 2025 Apr;75(2):840-848. doi: 10.1016/j.identj.2024.07.1208. Epub 2024 Sep 7.
Periodontitis, the main cause of tooth loss in adults, is a public health concern; its incidence increases with age, and its prevalence increases with increasing life expectancy of the population. Innovative therapies such as cell therapy represent promising future solutions for guided tissue regeneration. However, these therapies may be associated with fears and mistrust from the general public. The aim of this study was to estimate the acceptability of an advanced therapy medicinal product combining allogeneic mesenchymal stromal cells from adipose tissue with a natural fibrin hydrogel in the treatment of periodontitis.
The methodology was based on a qualitative study conducted through semi-structured interviews with patients followed for periodontitis in the Oral Medicine Department of the Toulouse University Hospital, Toulouse, France. Qualitative studies are essential methodologies to understand the patterns of health behaviours, describe illness experiences, and design health interventions in a humanistic and person-centred way of discovering.
Eleven interviews (with 4 men and 7 women) were required to reach thematic saturation. Analysis allowed 4 main themes to emerge: (1) perception of new treatments, science, and caregivers; (2) conditions that the treatment must meet; (3) patient perception of the disease; and (4) factors related to the content of the treatment.
Patients find cell therapy for periodontitis to be acceptable. If they express a need to be informed about the benefit/risk ratio, they are not particularly worried about side effects of the treatment, for either allogeneic or blood-derived products. Periodontitis is a prototypical model of chronic inflammatory pathology and is multitissular, with hard- and soft-tissue lesions. In a patient-centred approach, the success of cell therapy will require a bilateral, informed decision, taking into account potential therapeutic effectiveness and patient expectations for regeneration.
牙周炎是成年人牙齿缺失的主要原因，是一个公共卫生问题；其发病率随年龄增长而增加，患病率随人口预期寿命的延长而上升。细胞治疗等创新疗法是引导组织再生未来有前景的解决方案。然而，这些疗法可能会引起公众的恐惧和不信任。本研究的目的是评估一种先进治疗用药品（将来自脂肪组织的异体间充质基质细胞与天然纤维蛋白水凝胶结合用于治疗牙周炎）的可接受性。
该方法基于一项定性研究，通过对法国图卢兹大学医院口腔医学科随访的牙周炎患者进行半结构化访谈来实施。定性研究是理解健康行为模式、描述疾病经历以及以人文和以患者为中心的发现方式设计健康干预措施的重要方法。
需要进行11次访谈（4名男性和7名女性）才能达到主题饱和。分析得出4个主要主题：（1）对新治疗方法、科学和医护人员的认知；（2）治疗必须满足的条件；（3）患者对疾病的认知；（4）与治疗内容相关的因素。
患者认为用于治疗牙周炎的细胞疗法是可以接受的。如果他们表示需要了解获益/风险比，那么他们对治疗的副作用并不特别担心，无论是异体产品还是血液来源产品。牙周炎是慢性炎症病理学的典型模型，具有多组织性，存在硬组织和软组织病变。在以患者为中心的方法中，细胞治疗的成功需要双方做出明智的决定，同时考虑潜在的治疗效果和患者对再生的期望。
Zotero 插件